The $7M isn't anywhere near enough to fund the next 12 months including a Phase 2/3 Oxy trial, and the things we have in place at the moment (Le Metier, ISP, Elixia, and Phusion) won't be able to make up the shortfall. So, the money needs to come from either AOD or an upfront payment (or both).
At the moment, I'm not really interested in an announcement like a psoriasis, mastitis, or animal insulin, or dreaming of how many other applications there are for TPM, because they mean nothing in terms of the share price. The Novartis ann. was 12 months ago next week, and we've had several nice announcements since, but we've just had to issue shares at a lesser price than we did in the SPP in September 2009.
I don't want to read of something having 'generated significant commercial interest', or how big the global market for such-and-such a product is - I want to read that 'global company XYZ has agreed to pay us $X million'.
We could be near the start of something very big, but it had better start soon.
POH Price at posting:
9.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)